Market Overview

The market for Doxorubicin is majorly driven by the rising cases of cancer across the globe. As per the statistics provided by the National Cancer Institute (NCI), 1,762,450 new cancer cases and 606,880 cancer deaths are estimated for the year 2019. During the year 2018, the new cancer cases were around 1,735,350. The incidence of cancer given by the NCI is around 439.2 per 100,000 individuals per year.

Along with that, the mortality due to cancer is also on the rise and it is around 196.8 per 100,000 men and 139.6 per 100,000 women. During the year 2017, 15,270 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,790 were died due to the same.

However, in the year 2016, 15.5 million people were survived from cancer in the United States and this number is expected to reach up to 20.3 million by 2026. This indicates that due to the available treatment options, mortality due to the disease is being prevented and the same trend will be seen in the coming future.

Scope of the Report

Doxorubicin is a chemotherapy medication used to treat cancer. It is sold by the brand name Adriamycin® and Rubex® amongst others. It is indicated for various types of cancers including breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Breast Cancer is Believed to Witness Highest CAGR Over the Forecast Period

Despite the fact that Doxorubicin is used to treat several types of cancers, the most common cancer that can be treated with the same is Breast Cancer. Cancer has become the leading cause of death across the globe and there were around 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer, as stated by the World Health Organization (WHO).

According to WHO, the number of cases of Breast Cancer that were found in the year 2018 was around 2.09 million which is similar to that of lung cancer cases for that year. American Cancer Institute has stated that Doxorubicin is used during the advanced breast cancer treatment as a chemo drug. It is observed that currently, 3 million women diagnosed with breast cancer are there in the United States. Due to the rising burden of disease, a large number of people are going for the treatment which is ultimately helping the market studied to grow. Therefore, it is estimated that breast cancer segment will show rapid growth over the forecast period.

To understand key trends, Download Sample Report